Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-12

Clinical Trial Update: Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of ELND005 as an adjunctive maintenance treatment in Bipolar I Disorder was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ELND005

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Bipolar 1 Disorder | Phase 2 | Status: TERMINATED | Results posted: 2015-10-12